Join
Live feed
·
PRReleasevia Quantisnow
Chimerix Inc. logo

Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma

ByQuantisnow·Wall Street's wire, on your screen.
CMRX· Chimerix Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CMRX (Chimerix Inc.) and more on Quantisnow.